88IV - Public company info - Zhongzhi Pharmaceutical Holdings Limited

Input the stock code or the company name

Search

Financial Ratios

Zhongzhi Pharmaceutical Holdings Limited, 03737.HK - Company Profile
Chairman	Lai Zhi Tian
Share Issued (share)	840,000,000
Par Currency	Hong Kong Dollar
Par Value	0.01
Industry	Medicine
Corporate Profile	Business Summary: The Group is principally engaged in the manufacture and sale of pharmaceutical products (collectively the ‘‘Listing Business’’) in the People’s Republic of China (the ‘‘PRC’’). Performance for the year: Revenue of the Group rose by approximately 17.5% to approximately RMB1,342.2 million. Profit attributable to owners of the parent increased by approximately 34.8% to RMB114.7 million. Business Review： In 2019, Zhongzhi Pharmaceuticals successfully seized the opportunity of the Guangdong-Hong Kong-Macao Greater Bay Area and received strong support from the Guangdong Provincial Party Committee and Provincial Government. During his visit, Li Xi (member of the Political Bureau of the CPC Central Committee and Secretary of the Guangdong Provincial Committee) expressed his full affirmation of the Company’s achievements in the field of Chinese medicine innovation. He further encouraged us to continue investing in the Group’s technologies and people, strengthen the competitiveness and development potential of the Group’s Group, seize the opportunities of the Greater Bay Area, and take Chinese medicine international. In 2019, the Group achieved many breakthroughs around in the market: • The series of Chinese cell-broken decoction pieces have entered the Guangdong Medical Insurance Catalogue, which has further expanded user accessibility to the product and increased the market capacity. • The first “Healthy Guangdong” Herbal Health Festival was held to strengthen consumer awareness and recognition of the brand, which not only improved sales in the Group’s different channels, but also consolidated the market foundation. • Established a unique entrepreneurial partner model. The marketing and traditional Chinese medicine health professional training team helped the entrepreneurial partners to reach customers and maintain them throughout the year, creating several market benchmarks, and cultivated a number of impactful entrepreneurial partners. In 2019, the Group made several breakthroughs in scientific research technology: • The National Development and Reform Commission approved the establishment of the National and Local Joint Engineering Research Center for Chinese Herbal Broken Pieces, becoming the first nationallevel scientific research platform with Chinese Herbal Broken Pieces as the research and industrialization development direction. • Three self-developed Chinese medicine wall-breaking granule products have obtained the NPN (Natural Product Number) and license issued by the Health Canada and Natural Health Products Agency. • The Group’s laboratory obtained CNAS certification from China National Accreditation Service for Conformity Assessment, and its testing and inspection capabilities were recognized by ILAC. • The Chinese medicine broken wall decoction pieces were evaluated through non-clinical safety evaluation and clinical experiment research, and the quality controllability and uniformity were improved comprehensively, which provided scientific evidence for clinical application. • The Group was identified as a “National Intellectual Property Demonstration Enterprise” and its intellectual property management work has been recognized internationally. Prospects: In 2020, the epidemic of coronavirus pneumonia has brought huge difficulties to the Group’s society and economy, which had a certain impact on the development of the pharmaceutical industry. For pharmaceutical manufacturing, the shortage of materials, increasing costs of medicine and related packaging materials and logistics and transportation under the supply chain resulted in the increase in operating costs of many pharmaceutical enterprises. For chain pharmacies, the pressure on the operation of stores has increased due to the sharp decline in customer flow, the sluggish work resumption and the reduction in consumer purchasing power. Chinese medicine has played a key role in the diagnosis and treatment of this pneumonia epidemic. At present, despite the epidemic is rapidly being contained and the patients being recovered quickly as a result of the stringent and efficient measures implemented by the government in the PRC, the epidemic has been spreading rapidly around the world, which gives Chinese medicine a unique opportunity to exert its unique advantages. In addition to the existing capability of Chinese medicine in diagnosis and treatment, the increased application of Chinese medicine by the international community will promote Chinese medicine to be further recognised by more countries and people. As an innovative Chinese medicine enterprise in Guangdong Province, Zhongzhi Pharmaceutical has its own research platform and extensive resources of various experts and talents, which shall play a stronger role in the society in the “post-epidemic” era. In the pharmaceutical segment, the Group are confident to outperform the Group’s peers. In the chain pharmacies segment, the Group also believe that with the enhancement of service brands and the driving force of the pharmaceutical business, pioneering and innovative, pragmatic and enterprising, and winning new battles will also become a reality. Digital Management In 2019, the Group strengthened and improved the internal management processes which enhanced the overall management efficiency. With the Group’s effort in the second half of 2019, the business intelligence data system of the Group has been successfully launched, allowing management to have real time operating analytics at anytime and anywhere; improving the efficiency of decision makings. The Group will continue to invest in its information systems in 2020 to improve work efficiency and to increase employees’ awareness to data. Meanwhile, the Group will continue to stride towards the digital era, driving data-based decision making. Research and Development The Group continues to focus on the development of Caojinghua Cell-broken Herb (Chinese medicine cell wall broken decoction pieces) (草晶華破壁草本（中藥破壁飲片）) as its core development direction. In 2019, Caojinghua Cell-broken Herb has obtained international certification which received the regulatory approvals for three types of products in Canada. In the future, the Group will continue the Group’s effort in research and development focusing on the breakthrough of new decoction pieces, Chinese medicines, health supplements and SC Food Product Permit labelled products. The Group will echo the demands of the leaders in the Group’s government and continue to globalise Chinese Medicine.

Information from the financial statements of listed companies

88iv | Home | Login

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer

Copyright (C) 2024

Suntek Computer Systems Limited.

All rights reserved